1.709
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Cocrystal Pharma (NASDAQ:COCP) Stock Price Up 3.3% – Here’s Why - Defense World
Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-98 - GuruFocus
Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times
First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan
Cocrystal Pharma Presents to Investment Community - TipRanks
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq
Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia
What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World
COCP: Norovirus Challenge Study Planned for 2025… - MSN
Cocrystal Pharma, Inc. SEC 10-K Report - TradingView
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan
Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight - openPR.com
Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR
Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire
New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):